Curriculum Vitae (in brief)

Name : Sirous Zeinali
Position: Director, Iranian Molecular Medicine Network

Address : Work
Biotechnology Research Center, Dep't of Molecular Medicine,
Pasteur Institute of Iran

Tel: Work (98-2166480780)
Fax : (+9821 88939140)
Date of Birth: 26/5/59

EDUCATION

1969-1975 High School Diploma: Natural Science. Hashtroodi H.S., Tehran, Iran.
1979-1978 Associate Art: Biological Science. Shasta College, Redding, Cal, USA
1979-1980 B.Sc.: Molecular Biology. University of Oregon, USA.
1985-1988 PhD: Human Genetics, University of Glasgow, Scotland, UK.
1989-1990 MSc (Med. Sci): Medical Genetics, University of Glasgow, Scotland, UK.

Memberships / Positions

Deputy Director for Research, Pasteur Institute of Iran 10-05-07-07
Director, Iranian Molecular Medicine Network (Director, from its creation, 2001, till present).
Head, Department of Biotechnology, Pasture Institute of Iran (1992-2002).
Director, National Reference Center for Prenatal Diagnosis! (since 2000).
Head or Board Member of the Iranian Genetic Society, Iranian Biotechnology Society, Iranian Medical Genetics Society (currently head of the Biotech Soc. and Vice of Genetics Soc. till 6-2015).
Director of Medical Genetics Lab of Dr Zeinali
CEO, Kawsar Biotechnology Co.
Director of Kawsar Human Genetics Research Centre
Board member of several expert and policy making committees.

Work and Research

In 1992 I joined Pasteur Institute of Iran (PII). During this time decision had already been taken to establish a biotechnology department at PII. After equipping the department, it was officially opened in 1993. During these years I have worked mainly on medical genetics, carrier detection and prenatal diagnosis of different genetic disorders. I initiated molecular diagnostics of beta-globin gene mutations on thalassemic patients. This type of

study was initiated for the first time in the country. My main scientific activities have been on molecular analysis of alpha and beta-thalassemia, DMD/BMD and hemophilia.
I have done research on different subjects which some of them have been reflected in papers published in peer reviewed papers. Some these have been conducted in our private research center (Kawsar Human Genetics Research Center).

I have supervised several MSc, doctoral and PhD theses (more than 45 MSc, 8 doctoral and 35 PhD) and am supervising several theses now. I have taught several courses in medical genetics, genetic engineering, molecular genetics (more than 36 semesters till now). I have also organised several workshops and have given several talks as a guest speaker in Iran and abroad or participated in national or international conferences (more than 45).
I am the CEO of the Kawsar Biotech Co. This company was elected as knowledge based Company. The company has been engaged in several production and services in the area of genetics and biotechnology (www.kawsar.ir). Its Trastuzumab monoclonal antibody (Herceptin biosimilar) named Hersease® is in clinical trial phase and will be in the market in mid-2014. It's another antibody based drug (i.e. ATG or antithymocyte globulin) which is a polyclonal antibody is in the process of being evaluated by the regulatory body in the Ministry of Health.
We at the KBC have developed several molecular diagnostics kits and reagents. We have several national patents for our products. Our QF PCR kit (AneuQuick®) for aneuploidy detection will be in the market soon. Another kit is for human profiling named as IRfiler®. This kit contains 17 STR markers usually used for human profiling in the US and Europe. Another kit (Rizfiler®) is for profiling degraded DNA samples mainly for bone samples.

I have created a research, production and services center named Kawsar Genomics and Biotechnology Center. This center is the largest private center in Iran. We have more than 75 employees in the center with the average age of 26.
This center hosts Kawsar Human Genetics Research Center (KHGRC), Kawsar Biotech Company (KBC) (www.kawsar.ir) and Dr. Zeinali's Medical Genetics Medical Genetics Lab (www.medicalgnenticslab.ir). Dr. Zeinali's Medical Genetics Lab. (ZeMGeL) is the largest and one of the busiest medical genetics lab in the country.

Publications/chapter in book:
Sutcliffe RG, Nickson DA, Hundal AM, **Zeinali S**, McBride MW and Wang SLW (1990) **cDNA cloning and its application to cell surface proteins**. In gamete interaction: Prospects for immuno-contraception. PP. 436-460. Wiley-Liss, Inc., London.
Principle of PCR. Translation into Farsi: Mohsen Karimi, **Sirous Zeinali** (2004)
As the Future Catches You. Translation into Farsi: **Sirous Zeinali** , Farhad Bayat, Zohreh Nafissi. Ketabkhaneh Farhang, Tehran, Iran (2007). This book was revised and published again in 2009.

Publications: Full Papers:

1. Nickson DA, McBride MW, **Zeinali S**, Hawes CS, Petropoulos A, Mueller UW, Sutcliffe RG. Molecular cloning and expression of human trophoblast antigen FDO161G and its identification as 3 beta-hydroxy-5-ene steroid dehydrogenase. J Reprod Fertil. 1991 Sep;93(1):149-56.
2. Neerman-Arbez M, Antonarakis SE, Blouin JL, **Zeinali S**, Akhtari M, Afshar Y, Tuddenham EG. The locus for combined factor V-factor VIII deficiency (F5F8D) maps to 18q21, between D18S849 and D18S1103.
   Am J Hum Genet. 1997 Jul;61(1):143-50.
3. Peyvandi F, Mannucci PM, Lak M, Abdoullahi M, **Zeinali S**, Sharifian R, Perry D. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol. 1998 Jul;102(2):626-8.
4. Akhavan S, Rocha E, **Zeinali S**, Mannucci PM. Gly319 --> arg substitution in the dysfunctional prothrombin Segovia. Br J Haematol. 1999 Jun;105(3):667-9.
5. Duga S, Asselta R, Santagostino E, **Zeinali S**, Simonic T, Malcovati M, Mannucci PM, Tenchini ML. Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion.!Blood. 2000 Feb 15;95(4):1336-41.
6. Peyvandi F, Mannucci PM, Bucciarelli P, **Zeinali S**, Akhavan S, Sacchi E, Merlini PA, Perry DJ. A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. Br J Haematol. 2000 Feb;108(2):247-53.
7. Faioni EM, Hermida J, Rovida E, Razzari C, Asti D, **Zeinali S**, Mannucci PM. Type II protein C deficiency: identification and molecular modelling of two natural mutants with low anticoagulant and normal amidolytic activity. Br J Haematol. 2000 Feb;108(2):265-71.
8. **Zeinali S**, Duca F, Zarbakhsh B, Tagliabue L, Mannucci PM. Thrombophilic mutations in Iran. Thromb Haemost. 2000 Feb;83(2):351-2.
9. Peyvandi F, Jenkins PV, Mannucci PM, Billio A, **Zeinali S**, Perkins SJ, Perry DJ.
10. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost. 2000 Aug;84(2):250-7.
11. Azizi Z, Delmaghani S., Zeinali, M, Moghaddam Z and **Zeinali S.** The value of ARMS/PCR and RFLP/PCR in prenatal diagnostic accuracy of beta-thalassemia. Iranian Journal of Medical Sciences, Vol. 28, Nos 3 & 4, Dec. 2001.

12. Peyvandi F, Spreafico M, Karimi M, **Zeinali S**, Mannucci PM, Bianchi Bonomi A. Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb Haemost. 2002 Nov;88(5):874-5.
13. Karimi M, Yarmohammadi H, Farjadian S, **Zeinali S**, Moghaddam Z, Cappellini MD, Giordano PC.Beta-thalassemia intermedia from southern Iran: IVS-II-1 (G-->A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002 May; 26(2): 147-54.
14. Yassaee VR, **Zeinali S**, Harirchi I, Jarvandi S, Mohagheghi MA, Hornby DP, Dalton A. Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res. 2002;4(4).
15. Karimipoor M, **Zeinali S**, Lak M, Safaee R. Carrier testing and prenatal diagnosis of haemophilia B by SSCP in an Iranian family. Haemophilia. 2003 Jan;9(1):116-8.
16. Zakeri S, Dinparast Djadid N, **Zeinali S**. Sequence heterogeneity of the merozoite surface protein-1 gene (MSP-1) of Plasmodium vivax wild isolates in southeastern Iran. Acta Trop. 2003 Sep;88(1):91-7.
17. Delmaghani S, Aghaie A, Compain-Nouaille S, Ataie A, Lemainque A, **Zeinali S**, Lathrop M, Weil D, Petit C. DFNB40, a recessive form of sensorineural hearing loss, maps to chromosome 22q11.21-12.1. Eur J Hum Genet. 2003 Oct;11(10):816-8.
18. Willoughby CE, Arab S, Gandhi R, **Zeinali S**, Arab S, Luk D, Billingsley G, Munier FL, Heon E. A novel GJA8 mutation in an Iranian family with progressive autosomal dominant congenital nuclear cataract. J Med Genet. 2003 Nov;40(11): e124.
19. Abdolhossein Rezaeian, Mohammad hossein Alimohammadian and **Sirous Zeinali.** Microsatellite analysis of mouse TNF and Cypla2 loci for polymorphism: detection and evaluation of genetic contamination. Scand. J. Lab. Anim. Sci. No. 3. 2003. Vol. 30
20. Zahedmehr A., S. Delmaghani, R. Sharifian, M. Lak, **S. Zeinali.** The Frequencies of three Factor IX-Linked Restriction Fragment Length Polymorphisms in Iranian Patients with Hemophilia B. IJMS Vol 29, No 1, March 2004.
21. Ghandil P, Ghadiri A, Farhud D, **Zeinali S**. Allele frequencies of two polymorphisms associated with the factor IX gene in Iranian population. Thromb Res. 2004;113(5):289-93.
22. Sepehr A, Kamangar F, Abnet CC, Fahimi S, Pourshams A, Poustchi H, **Zeinali S,** Sotoudeh M, Islami F, Nasrollahzadeh D, Malekzadeh R, Taylor PR,

Dawsey SM. Genetic polymorphisms in three Iranian populations with different risks of esophageal cancer, an ecologic comparison. Cancer Lett. 2004 Sep 30;213(2):195-202.

23. Morteza Karimipoor, **Sirous Zeinal**i, Reza Safaee, Manijheh Lak, Nafiseh Nafissi Carrier determination in a Hemophilia B family using single strand conformation polymorphism (SSCP) and sequencing. IRANIAN JOURNAL of BIOTECHNOLOGY, Vol. 2, No. 2, April 2004 132.
24. Ahmadreza Niavarani1, Sirous Zeinali1, Mohsen Karimi1, and Minoo Rassoulzadegan2 Development of transgenic mice harboring ovine beta lactoglobulin-calcitonin transgene. IRANIAN JOURNAL of BIOTECHNOLOGY, Vol. 2, No. 3, July 2004
25. Fard-Esfahani P, Khatami **S, Zeinali** C, Taghikhani M, Allahyari M.!A modified conformation sensitive gel electrophoresis (CSGE) method for rapid and accurate detection of low density lipoprotein (LDL) receptor gene mutations in Familial Hypercholesterolemia. Clin Biochem. 2005 Jun;38(6):579-83.
26. Pejman Fard-Esfahani, **Sirous Zeinali**, Soghra Rouhi Dehboneh, Mohhammad Taghikhani and Shohreh Khatami A Novel Mutation in Exon 4 of the Low Density Lipoprotein (LDL) Receptor Gene in an Iranian Familial Hypercholesterolemia Patient Iranian Biomedical Journal 9 (3): 139-142 (July 2005)
27. Niavarani A, Dehghanizadeh S, **Zeinali S**, Karimi M, Magliano M, Rassoulzadegan M. Development of Transgenic Mice Expressing Calcitonin as a Beta-lactoglobulin Fusion Protein in Mammary Gland. Transgenic Res. 2005 Oct;14(5):719-27.
28. Azimifar B. S., S. Yoosef Seyedna, **Sirous Zeinali**. The value of St14 (DXS52) VNTR analysis for genetic diagnosis of hemophilia A in Iranian population. Thromb Res. 2005 Nov 30.
29. Eram SM, Azimifar B, Abolghasemi H, Foulady P, Lotfi V, Masrouri M, Hosseini M, Abdolhosseini A**, Zeinali S**. The IVS-II-1 (G-->a) beta0-thalassemia mutation in cis with HbA2-Troodos [delta116(G18)Arg-->Cys (CGC-->TGC)] causes a complex prenatal diagnosis in an Iranian family. Hemoglobin. 2005;29(4):289-92.
30. Khanahmad H, Noori Daloii MR, Shokrgozar MA, Azadmanesh K, Niavarani AR, Karimi M, Rabbani B, Khalili M, Bagheri R, Maryami F, **Zeinali S.** A novel single step double positive double negative selection strategy for beta-globin gene replacement. Biochem Biophys Res Commun. 2006 Jun 23;345(1):14-20.

31. Azimifar SB, Seyedna SY, **Zeinali S.** Allele frequencies of three factor VIII gene polymorphisms in Iranian populations and their application in hemophilia A carrier detection. Am J Hematol. 2006 May;81(5):335-9.
32. **Zeinali S**, Mohammad Eram S, Azimifar SB, Lotfi V, Foulady P, Masrouri M. First report on the co-inheritance of (beta) IVS I-1 (G-->T) Thalassemia with the (gamma) CD85 [Phe-->Ser (F1) (TTT-->TCT)] HbA2 Etolia in Iran. Haematologica. 2006 Jun;91(6 Suppl):ECR15.
33. Karimipoor M, **Zeinali S**, Nafissi N, Tuddenham EG, Lak M, Safaee R. Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing. Thromb Res. 2007;120(1):135-9. Epub 2006 Oct 2.
34. Abolghasemi H, Amid A, **Zeinali S**, Radfar MH, Eshghi P, Rahiminejad MS, Ehsani MA, Najmabadi H, Akbari MT, Afrasiabi A, Akhavan-Niaki H, Hoorfar H. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007 Apr; 29(4):233-8.
35. Khatami S, Dehboneh SR, Sadeghi S, Mirzazadeh R, Saeedi P, Bayat P, Najmabadi H, **Zeinali S**, Akbari MT, Ardjmand M, Amirkhani A. Globin chain synthesis is a useful complementary tool in the differential diagnosis of thalassemias. Hemoglobin. 2007; 31(3):333-41.
36. Kiani AA, Mortazavi Y, **Zeinali S**, Shirkhani Y. The molecular analysis of beta-thalassemia mutations in Lorestan Province, Iran. Hemoglobin. 2007;31(3):343-9.
37. Rabbani B, Rezaeian A, Khanahmad H, Bagheri R, Kamali E, **Zeinali S**. Analysing two dinucleotide repeats of FVIII gene in Iranian population. Haemophilia. 2007 Nov;13(6):740-4.
38. Rabbani B, Khanahmad H, Bagheri R, Mahdieh N, **Zeinali S**. Characterization of minor bands of STR amplification reaction of FVIII gene by PCR cloning. Clin Chim Acta. 2008 Aug;394(1-2):114-5
39. Karimipoor M, Kokabee L, Kamali E, Karizi SZ, **Zeinali S**. Molecular analysis of factor IX gene in an Iranian female with severe hemophilia B. Acta Haematol. 2008;119(3):151-3. Epub 2008 Apr 24.
40. Gheisari Y, Soleimani M, Azadmanesh K, **Zeinali S**. Multipotent mesenchymal stromal cells: optimization and comparison of five cationic polymer-based gene delivery methods. Cytotherapy. 2008;10(8):815-23.
41. Babashah S, Jamali S, Mahdian R, Nosaeid MH, Karimipoor M, Maryami F, Raeisi M, Alimohammadi R, Masoudifar M, **Zeinali S**. Detection of unknown

deletions in beta-globin gene cluster using relative quantitative PCR methods Eur J Haematol. 2009 Apr 1.

42. Hayat Nosaeid M, Mahdian R, Jamali S, Maryami F, Babashah S, Maryami F, Karimipoor M, **Zeinali S** Validation and comparison of two quantitative real-time PCR assays for direct detection of DMD/BMD carriers. Clin Biochem. 2009 Aug;42(12):1291-9.

43. Hamid M, Mahjoubi F, Akbari MT, **Zeinali S**, Karimipoor M. The Cretan type of nondeletional hereditary persistence of fetal hemoglobin in an Iranian family. Ann Hematol. 2009 Dec;88(12):1267-8.

44. Gheisari Y, Soleimani M, **Zeinali S**, Arefian E, Atashi A, Zarif MN. Isolation of stem cells from adult rat kidneys. Biocell. 2009 Apr;33(1):33-8.

45. Fallah MS, Zadeh-Vakili A, Aleyasin SA, Mahdian R, Karimipour M, Raeisi M, Jamali S, Ebrahimi A, Fooladi P, Naderi M, Baysal E, **Zeinali S**. Molecular characterization of thalassemia intermedia, due to co-inheritance of homozygous alpha triplication and IVSI-5 beta-thalassemia. Blood Cells Mol Dis. 2009 Jul 2.

46. Daneshpour MS, Alfadhli S, Houshmand M, **Zeinali S**, Hedayati M, Zarkesh M, Momenan AA, Azizi F. Allele Frequency Distribution Data for D8S1132, D8S1779, D8S514, and D8S1743 in Four Ethnic Groups in Relation to Metabolic Syndrome: Tehran Lipid and Glucose Study. Biochem Genet. 2009 Oct;47(9-10):680-7!

47. Suri F, Yazdani S, Narooie-Nejhad M, Zargar SJ, Paylakhi SH, Zeinali S, Pakravan M, Elahi E. Variable expressivity and high penetrance of CYP1B1 mutations associated with primary congenital glaucoma. Ophthalmology. 2009 Nov;116(11):2101-9.

48. Fallah MS, Samavat A, Zeinali S. Iranian national program for the prevention of thalassemia and prenatal diagnosis : mandatory premarital screening and legal medical abortion. Prenat Diagn. 2009 Dec;29(13):1285-6

49. Valaei A, Bayat F, Kordafshari A, Zeinali S, Karimipoor M. A novel polymorphism causes a different restriction pattern by RsaI in the beta-globin gene cluster: application in prenatal diagnosis. Hemoglobin. 2009;33(6):417-21.

50. Hamid M, Mahjoubi F, Akbari MT, Arab A, Zeinali S, Karimipoor M. Molecular analysis of gamma-globin promoters, HS-111 and 3'HS1, in beta-thalassemia intermedia patients associated with high levels of Hb F. Hemoglobin. 2009; 33(6):428-38.

51. Teimoori-Toolabi L, Azadmanesh K, Zeinali S. Selective suicide gene therapy of colon cancer cell lines exploiting fibroblast growth factor 18 promoter. Cancer Biother Radiopharm. 2010 Feb;25(1):105-16.
52. Teimoori-Toolabi L, Azadmanesh K, Amanzadeh A, Zeinali S. Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. BioDrugs. 2010 Apr 1;24(2):131-46.
53. Fallah MS, Mahdian R, Aleyasin SA, Jamali S, Hayat-Nosaeid M, Karimipour M, Raeisi M, Zeinali S. Development of a quantitative real-time PCR assay for detection of unknown alpha-globin gene deletions. Blood Cells Mol Dis. 2010 Jun 15;45(1):58-64.
54. Gheisari Y, Nassiri SM, Arefian E, Ahmadbeigi N, Azadmanesh K, Jamali M, Jahanzad I, Zeinali S, Vasei M, Soleimani M. Severely damaged kidneys possess multipotent renoprotective stem cells. Cytotherapy. 2010 May;12(3):303-12.
55. Teimoori-Toolabi L, Vahedi H, Mollahajian H, Kamali E, Hajizadeh-Sikaroodi S, Zeinali S, Tabrizian T, Olfati G, Rashtak S, Malekzadeh F, Ghoddosi A, Malekzadeh R. Three common CARD15 mutations are not responsible for the pathogenesis of Crohn's disease in Iranians. Hepatogastroenterology. 2010 Mar-Apr;57(98):275-82.
56. Mahdieh N, Bagherian H, Shirkavand A, Sharafi M, Zeinali S. High level of intrafamilial phenotypic variability of non-syndromic hearing loss in a Lur family due to delE120 mutation in GJB2 gene. Int J Pediatr Otorhinolaryngol. 2010 Sep;74(9):1089-91.
57. Inanlou DN, Yakhchali B, Khanahmad H, Gardaneh M, Movassagh H, Cohan RA, Ardestani MS, Mahdian R, Zeinali S. Towards beta-globin gene-targeting with integrase-defective lentiviral vectors. Biotechnol Lett. 2010 Nov;32(11):1615-21
58. Mahdieh N, Rabbani B, Wiley S, Akbari MT, Zeinali S. Genetic causes of nonsyndromic hearing loss in Iran in comparison with other populations. J Hum Genet. 2010 Oct;55(10):639-48
59. Mahdieh N, Shirkavand A, Raeisi M, Akbari MT, Tekin M, **Zeinali S**. Unexpected heterogeneity due to recessive and de novo dominant mutations of GJB2 in an Iranian family with nonsyndromic hearing loss: implication for genetic counseling.Biochem Biophys Res Commun. 2010 Nov 12;402(2):305-7.
60. Amirian A, Jafarinejad M, Kordafshari AR, Mosayyebzadeh M, Karimipoor M, **Zeinali S**. Identification of a novel δ-globin gene mutation in an Iranian family. Hemoglobin. 2010;34(6):594-8.

61. Mahdieh N, Raeisi M, Shirkavand A, Bagherian H, Akbari MT, **Zeinali S**. Investigation of GJB6 large deletions in Iranian patients using quantitative real-time PCR. Clin Lab. 2010;56(9-10):467-71.
62. Arab A, Karimipoor M, Rajabi A, Hamid M, Arjmandi S, **Zeinali S**. Molecular characterization of β-thalassemia intermedia: a report from Iran. Mol Biol Rep. 2011 Oct;38(7):4321-6.
63. Amirian A, Karimipoor M, Jafarinejad M, Taghavi M, Kordafshari A, Fathi Azar S, Mohammadi MS, **Zeinali S**. First report on the co-inheritance of beta-globin IVS-I-5 (G-->C) thalassemia with delta globin CD12 {Asn-->Lys (AAT-->AAA)}HbA_2-NYU in Iran. Arch Iran Med. 2011 Jan;14(1):8-11.
64. Taghavi Basmanj M, Karimipoor M, Amirian A, Jafarinejad M, Katouzian L, Valaei A, Bayat F, Kordafshari A, **Zeinali S**. Co-inheritance of hemoglobin D and β-thalassemia traits in three Iranian families: clinical relevance. Arch Iran Med. 2011 Jan;14(1):61-3.
65. Mahdieh N, Rabbani B, Shirkavand A, Bagherian H, Movahed ZS, Fouladi P, Rahiminejad F, Masoudifard M, Akbari MT, **Zeinali S**. Impact of consanguineous marriages in GJB2-related hearing loss in the Iranian population: a report of a novel variant. Genet Test Mol Biomarkers. 2011 Jul-Aug;15(7-8):489-93.
66. Daneshpour MS, Rebai A, Houshmand M, Alfadhli S, **Zeinali S**, Hedayati M, Zarkesh M, Azizi F. 8q24.3 and 11q25 chromosomal loci association with low HDL-C in metabolic syndrome. Eur J Clin Invest. 2011 Oct;41(10):1105-12.
67. **Zeinali S**, Fallah MS, Bagherian H. Heterogeneity of hemoglobin h disease in childhood. N Engl J Med. 2011 May 26;364(21):2070-1
68. Hamid M, Mahjoubi F, Akbari MT, Khanahmad H, Jamshidi F, **Zeinali S**, Karimipoor M. Transient expression assay of Agamma-588 (A/G) mutations in the K562 cell line. Iran Biomed J. 2011 Jan-Apr;15(1-2):15-21.
69. Moosavi SF, Amirian A, Zarbakhsh B, Kordafshari A, Mirzahoseini H, **Zeinali S**, Karimipoor M. The carrier frequency of α-globin gene triplication in an Iranian population with normal or borderline hematological parameters. Hemoglobin. 2011;35(4):323-30.
70. Rahiminejad MS, **Zeinali S**, Afrasiabi A, Valeshabad AK. β-Thalassemia mutations found during 1 year of prenatal diagnoses in Fars Province, Iran. Hemoglobin. 2011;35(4):331-7.
71. Keshavarzi F, Javadi GR, **Zeinali S**. BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Fam Cancer. 2012 Mar;11(1):57-67

72. Safinejad K, Darbouy M, Kalantar SM, **Zeinali S**, Mirfakhraie R, Yadegar L, Houshmand M. The prevalence of common CFTR mutations in Iranian infertile men with non-CAVD obstructive azoospermia by using ARMS PCR techniques. J Assist Reprod Genet. 2011 November; 28(11): 1087–1090.
73. Behdani M, **Zeinali S**, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, Khabiri A, Schoonooghe S, Habibi Anbouhi M, Hassanzadeh-Ghassabeh G, Muyldermans S.Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol. 2012 Feb;50(1-2):35-41
74. Gheisari Y, Azadmanesh K, Ahmadbeigi N, Nassiri SM, Golestaneh AF, Naderi M, Vasei M, Arefian E, Mirab-Samiee S, Shafiee A, Soleimani M, **Zeinali S**. Genetic modification of mesenchymal stem cells to overexpress CXCR4 and CXCR7 does not improve the homing and therapeutic potentials of these cells in experimental acute kidney injury.Stem Cells Dev. 2012 Nov 1;21(16):2969-80
75. Mahdieh N, Shirkavand A, Rabbani B, Tekin M, Akbari B, Akbari MT, **Zeinali S**. Screening of OTOF mutations in Iran: a novel mutation and review. Int J Pediatr Otorhinolaryngol. 2012 Nov;76(11):1610-5
76. Ghasemi A, Mahdieh N, Tavallaei M, Aslani MM, Zafari Z, Shirkavand A, Farzad MS, Naderi M, Azariyan SH, **Zeinali S**. Design of a biological method for rapid detection of presence of PCR inhibitors in aged bone DNA. Clin Lab. 2012;58(7-8):681-6.
77. Behdani M, **Zeinali S**, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A, Seyed N, Moazami-Godarzi R, Baniahmad F, Habibi-Anbouhi M, Hassanzadeh-Ghassabeh G, Muyldermans S. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N Biotechnol. 2013 Jan 25;30(2):205-9.
78. Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, **Zeinali S**. In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin. Adv Biomed Res. 2012;1:21
79. Behdani M, **Zeinali S**, Karimipour M, Khanahmad H, Asadzadeh N, Azadmanesh K, Seyed N, Baniahmad SF, Anbouhi MH. Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2. Adv Biomed Res. 2012;1:34.
80. Maryami F, Mahdian R, Jamali S, Karimi Arzanani M, Khatami S, Maryami F, Bayat P, Sadeghi S, Karimipour M, **Zeinali S**. Comparisons between RT-PCR,

real-time PCR, and in vitro globin chain synthesis by α/β ratio calculation for diagnosis of α- from β-thalassemia carriers. Arch Iran Med. 2013 Apr;16(4):217-20.

81. Davoudi-Dehaghani E, **Zeinali S**, Mahdieh N, Shirkavand A, Bagherian H, Tabatabaiefar MA. A transversion mutation in non-coding exon 3 of the TMC1 gene in two ethnically related Iranian deaf families from different geographical regions; evidence for founder effect. Int J Pediatr Otorhinolaryngol. 2013 May;77(5):821-6.
82. Khatami S, Dehnabeh SR, Mostafavi E, Kamalzadeh N, Yaghmaei P, Saeedi P, Shariat F, Bagheriyan H, **Zeinali S**, Akbari MT. Evaluation and Comparison of Soluble Transferrin Receptor in Thalassemia Carriers and Iron Deficient Patients. Hemoglobin. 2013;37(4):387-95.Apr 12.
83. Sharafi Farzad M, Tomas C, Børsting C, Zeinali Z, Malekdoost M, **Zeinali S**, Morling N. Analysis of 49 autosomal SNPs in three ethnic groups from Iran: Persians, Lurs and Kurds. Forensic Sci Int Genet. 2013 May
84. Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, **Zeinali S**. Expression Enhancement in Trastuzumab Therapeutic Monoclonal Antibody Production using Genomic Amplification with Methotrexate. Avicenna J Med Biotechnol. 2013 Apr;5(2):87-95.
85. Kainimoghaddam Z, Valaei A, Bayat F, Taghavi Basmanj M, Navabmoghaddam F, Mortezazadeh M, Teimoori-Toolabi L, Ahmadi S, Sadegh S, Kordafshari A, Karimipoor M, **Zeinali S**. Prenatal diagnosis of β-thalassemia in twin pregnancies in Iran. Arch Iran Med. 2013 Oct;16(10):573-5
86. Raeisi M, Mahdieh N, Yousefzadeh A, Vahidi R, Rahimi N, **Zeinali S**. A novel PCBD gene mutation in an Iranian patient with hyperphenylalaninemia. Clin Lab. 2013;59(7-8):925-8.
87. Davoudi-Dehaghani E, Fallah MS, Shirzad T, Tavakkoly-Bazzaz J, Bagherian H, **Zeinali S**. Reporting the presence of three different diseases causing GJB2 mutations in a consanguineous deaf family. Int J Audiol. 2014 Feb;53(2):128-31
88. Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P, **Zeinali S**. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 2014 Jan 21;15(4).
89. Arezumand R, Mahdian R, Behdani M, Khanahmad H, Langari J, Namvarasl N, Hassanzadeh-Ghasabeh R, **Zeinali S**. Recombinant expression and purification

of human placental growth factor 1 and specific camel heavy chain polyclonal antibody preparation. Saudi J Biol Sci. 2014 Jan;21(1):35-9

Also more than 40 Papers in Farsi and several in preparation

Abstracts:

More than 500 abstracts presented at national and international conferences.